Sitagliptin (DPP-4 inhibitor)-induced rheumatoid arthritis in type 2 diabetes mellitus: A case report

Internal Medicine

Volumn 51, Issue 15, 2012, Pages 2041-2044

  Yokota, Kazuki ^a,b   Igaki, Naoya ^b  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Takasago Municipal Hospital   (Japan)

Author keywords

Dipeptidyl peptidase (DPP) 4 inhibitor; Human leukocyte antigen (HLA); Rheumatoid arthritis

Indexed keywords

ANTINUCLEAR ANTIBODY; C REACTIVE PROTEIN; DIPEPTIDYL PEPTIDASE IV; MIGLITOL; NATEGLINIDE; NONSTEROID ANTIINFLAMMATORY AGENT; RHEUMATOID FACTOR; SITAGLIPTIN;

ADULT; ARTHRALGIA; ARTICLE; CASE REPORT; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; HEADACHE; HUMAN; JOINT SWELLING; NON INSULIN DEPENDENT DIABETES MELLITUS; RHEUMATOID ARTHRITIS;

ALLELES; ARTHRITIS, RHEUMATOID; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HLA-DRB1 CHAINS; HUMANS; MIDDLE AGED; PYRAZINES; RHEUMATOID FACTOR; TRIAZOLES;

EID: 84864524440     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.51.7592     Document Type: Article

References (16)

1. Busso N, Wagtmann N, Herling C, et al. Circulating CD26 is negatively associated with inflammation in human and experimental arthritis. Am J Pathol 166: 433-442, 2005.
2. The Committee of Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Journal of Diabetes Investigation 1: 212-228, 2010.
3. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69: 1580-1588, 2010.
4. Muscat C, Bertotto A, Agea E, et al. Expression and functional role of 1F7 (CD26) antigen on peripheral blood and synovial fluid T cells in rheumatoid arthritis patients. Clin Exp Immunol 98: 252-256, 1994.
5. Cordero OJ, Salgado FJ, Mera-Varela A, Nogueira M. Serum interleukin-12, interleukin-15, soluble CD26, and adenosine deaminase in patients with rheumatoid arthritis. Rheumatol Int 21: 69-74, 2001.
6. Cuchacovich M, Gatica H, Pizzo SV, Gonzalez-Gronow M. Characterization of human serum dipeptidyl peptidase IV (CD26) and analysis of its autoantibodies in patients with rheumatoid arthritis and other autoimmune diseases. Clin Exp Rheumatol 19: 673-680, 2002.
7. Konig A, Krenn V, Toksoy A, Gerhard N, Gillitzer R. Mig, GRO alpha and RANTES messenger RNA expression in lining layer, infiltrates and different leucocyte populations of synovial tissue from patients with rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Virchows Archiv 436: 449-458, 2000.
8. Loetscher P, Moser B. Homing chemokines in rheumatoid arthritis. Arthritis Res 4: 233-236, 2002.
9. Sedo A, Duke-Cohan JS, Balaziova E, Sedova LR. Dipeptidyl peptidase IV activity and/or structure homologs: contributing factors in the pathogenesis of rheumatoid arthritis? Arthritis Res Ther 7: 253-269, 2005.
10. Ospelt C, Mertens JC, Jüngel A, et al. Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 62: 1224-1235, 2010.
11. van der Helm-van Mil AH, Huizinga TW. Advances in the genetics of rheumatoid arthritis point to subclassification into distinct disease subsets. Arthritis Res Ther 10: 205, 2008.
12. Huizinga TW, Amos CI, van der Helm-van Mil AH, et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum 52: 3433-3438, 2005.
13. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Huizinga TW, Toes RE, de Vries RR. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum 54: 1117-1121, 2006.
14. Balsa A, Cabezón A, Orozco G, et al. Influence of HLA DRB1 alleles in the susceptibility of rheumatoid arthritis and the regulation of antibodies against citrullinated proteins and rheumatoid factor. Arthritis Res Ther 12: R62, 2010.
15. Irigoyen P, Lee AT, Wener MH, et al. Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: contrasting effects of HLADR3 and the shared epitope alleles. Arthritis Rheum 52: 3813-3818, 2005.
16. Verpoort KN, van Gaalen FA, van der Helm-van Mil AH, et al. Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis. Arthritis Rheum 52: 3058-3062, 2005.